Ranolazine Improves Glycemic Variability and Endothelial Function in Patients with Diabetes and Chronic Coronary Syndromes: Results from an Experimental Study
Table 1
Baseline characteristics of the two cohorts.
Ranolazine ()
No ranolazine ()
value
Age (years)
0.268
Female gender
4 (25)
4 (25)
—
BMI (kg/m2)
0.224
Dyslipidemia
14 (88)
12 (75)
0.365
Hypertension
15 (94)
15 (94)
—
Smoking
10 (63)
11 (69)
0.709
Diabetes on oral GLAs
12 (75)
8 (50)
0.273
Diabetes on insulin therapy
3(19)
5 (31)
0.685
Diabetes on oral GLAs and insulin
1 (6)
3 (19)
0.597
Previous PCI
12 (75)
11(69)
0.694
Previous CABG
3 (19)
3 (19)
—
LVEF (%)
0.089
Angina (CCS III-IV)
5 (31)
1 (6)
0.172
Multivessel disease
12 (75)
11 (69)
0.694
Haemoglobin (g/dl)
0.375
Creatinine (mg/dl)
0.086
GFR (ml/min/1.73 m2)
0.364
Statins
14 (88)
15 (94)
0.544
Beta-blockers
12 (75)
12 (75)
—
ACE-inhibitors/ARBs
13 (81)
16 (100)
—
Nitrates
10(63)
11 (69)
0.709
Calcium-channel blockers
8 (50)
11 (69)
0.472
Biguanides
11 (69)
9 (56)
0.716
Sulfonylureas
5 (31)
1 (6)
0.172
Meglitinides
3(19)
2 (13)
1
TZD
0
0
—
DPP-4 inhibitors
3 (19)
2 (13)
1
SGLT-2 inhibitors
0
1 (6)
—
GLP-1 agonists
0
0
—
Insulin
4 (25)
8 (50)
0.273
Values are or (%). ACE: angiotensin-converting enzyme; ARB: angiotensin receptor blockers; BMI: body mass index; CABG: coronary artery bypass surgery; CCS: Canadian Cardiovascular Society; DPP: 4-dipeptidyl-peptidase 4; GLA: glucose-lowering agents; GLP-1: glucagon-like peptide 1; GFR: glomerular filtration rate; LVEF: left ventricular ejection fraction; PCI: percutaneous coronary intervention; SGLT2: sodium-glucose transporter 2; TZD: thiazolidinediones.
